Get the Stockscreener App
0.2996
5.37%
-0.017
After Hours:
.29
-0.0096
-3.20%
Cellectar Biosciences Inc stock is traded at $0.2996, with a volume of 12.92M.
It is down -5.37% in the last 24 hours and up +6.62% over the past month.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.
See More
Previous Close:
$0.3166
Open:
$0.3196
24h Volume:
12.92M
Relative Volume:
4.67
Market Cap:
$13.81M
Revenue:
-
Net Income/Loss:
$-37.75M
P/E Ratio:
-0.0922
EPS:
-3.25
Net Cash Flow:
$-30.91M
1W Performance:
-2.22%
1M Performance:
+6.62%
6M Performance:
-85.93%
1Y Performance:
-91.54%
1-Day Range:
$0.278
$0.3196
1-Week Range:
$0.278
$0.3364
52-Week Range:
$0.224
$4.17
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Name
Cellectar Biosciences Inc
Sector
Industry
Phone
(608) 441-8120
Address
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Compare CLRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
0.2996 | 13.81M | 0 | -37.75M | -30.91M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Resumed | Ladenburg Thalmann | Buy |
| Jul-01-20 | Initiated | Oppenheimer | Outperform |
| Jan-21-20 | Resumed | ROTH Capital | Buy |
| Sep-13-19 | Initiated | ROTH Capital | Buy |
| Dec-21-16 | Initiated | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc Stock (CLRB) Latest News
Cellectar Biosciences Earnings Call: Mixed Outlook Amid Successes and Challenges - TipRanks
Earnings call transcript: Cellectar Biosciences Q4 2024 sees restructuring amid losses - Investing.com
Cellectar's Breakthrough: 83.6% Response Rate Puts FDA Fast Track Within Reach - StockTitan
Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update - GlobeNewswire
Cellectar Biosciences COO acquires $8,400 in stock By Investing.com - Investing.com Canada
Cellectar Biosciences COO acquires $8,400 in stock - Investing.com India
Cellectar Biosciences Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Cellectar Biosciences, Inc. to Present at 37th Annual Roth Conference - Nasdaq
Cellectar Biosciences to Present at the 37th Annual Roth Conference - Enid News & Eagle
Cancer Treatment Breakthrough? Cellectar Biosciences Reveals Latest Progress at Major Investor Conference - StockTitan
Before You Invest, Make Sure You Check This Cellectar Biosciences Inc (NASDAQ: CLRB) Analysis - Stocks Register
Cellectar Biosciences (NASDAQ:CLRB) Now Covered by Analysts at StockNews.com - Defense World
Cellectar Biosciences (CLRB) Expected to Announce Quarterly Earnings on Thursday - Defense World
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025 - GlobeNewswire
Cellectar Biosciences, Inc. to Report 2024 Financial Results and Corporate Update on March 13, 2025 - Nasdaq
When Will Cellectar Biosciences Reveal Its 2024 Financial Performance? - StockTitan
StockNews.com Initiates Coverage on Cellectar Biosciences (NASDAQ:CLRB) - Defense World
Cellectar Biosciences (NASDAQ:CLRB) Coverage Initiated at StockNews.com - Defense World
CLRB’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Prepare Yourself for Liftoff: Cellectar Biosciences Inc (CLRB) - SETE News
StockNews.com Begins Coverage on Cellectar Biosciences (NASDAQ:CLRB) - Defense World
SEC Form 424B3 filed by Cellectar Biosciences Inc. - Quantisnow
A look into Cellectar Biosciences Inc (CLRB)’s deeper side - SETE News
Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Cellectar Biosciences, Inc. to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 - Nasdaq
Cellectar Biosciences Showcases Cancer Treatment Pipeline at Major Healthcare Conference - StockTitan
Examining Cellectar Biosciences Inc (CLRB) stock is warranted - US Post News
Cellectar faces Nasdaq delisting over share price rule - MSN
Market Momentum Report: Cellectar Biosciences Inc (CLRB)’s Positive Close at 0.26 - The Dwinnex
Rosalind Advisors, Inc. Increases Stake in Cellectar Biosciences Inc - GuruFocus.com
Cellectar faces Nasdaq delisting over share price rule By Investing.com - Investing.com Australia
Cellectar Biosciences (NASDAQ:CLRB) Now Covered by StockNews.com - Defense World
Barclays PLC Trims Stake in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World
Cellectar Biosciences (STU:NV4) Enterprise Value : €-9.79 Mil (As of Jan. 19, 2025) - GuruFocus.com
Mustang Bio (NASDAQ:MBIO) Stock Quotes, Forecast and News Summary - Benzinga
Cellectar Biosciences (FRA:NV4) Gross Margin % : 0.00% (As of Sep. 2024) - GuruFocus.com
Cellectar Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Oppenheimer keeps Perform rating on Cellectar Biosciences stock on recent update - Investing.com Canada
Cellectar Biosciences (NASDAQ:CLRB) Earns Sell Rating from Analysts at StockNews.com - Defense World
Cellectar Biosciences to Highlight 2025 Strategic - GlobeNewswire
Cellectar's Cancer Drug Iopofosine Achieves Remarkable 83.6% Response Rate in Phase 2 Trial - StockTitan
S&P Midcap 400 (IDX) QuotePress Release - The Globe and Mail
S&P Smallcap 600 (IQY) QuotePress Release - The Globe and Mail
Barclays PLC Has $258,000 Holdings in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World
Cellectar stock plunges 50% post-market on restructuring news - MSN
Wall Street’s top 5 stocks with the biggest upside in 2025Finbold - Finbold - Finance in Bold
Is Now The Time To Buy Cellectar Biosciences Inc (NASDAQ: CLRB) Stock? - Stocks Register
Cellectar Biosciences Inc Stock (CLRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):